NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
34.44
-1.81 (-4.99%)
At close: Apr 14, 2026, 4:00 PM EDT
34.50
+0.06 (0.17%)
After-hours: Apr 14, 2026, 5:06 PM EDT

NAMS Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
490771.74340.45467.7360.37
Short-Term Investments
146.2462.45---
Cash & Short-Term Investments
636.24834.19340.45467.7360.37
Cash Growth
-23.73%145.03%-27.21%674.73%-
Other Receivables
-4.95---
Total Trade Receivables
-4.95---
Other Current Assets
39.4624.276.3410.256.57
Total Current Assets
675.7863.41346.79477.9866.95
Net Property, Plant & Equipment
0.570.670.10.150.22
Other Intangible Assets
0.410.5388.788.7-
Long-Term Investments
92.61----
Other Long-Term Assets
--0.040.160.82
Total Assets
769.28864.62435.62566.9967.98
Accounts Payable
8.974.7416.9211.8511.17
Accrued Expenses
15.4213.6114.887.88-
Current Portion of Leases
0.140.250.060.070.06
Unearned Revenue
3.996.018.9413.87-
Other Current Liabilities
57.2782.3112.574.15-
Total Current Liabilities
85.79106.9253.3837.8211.24
Long-Term Leases
0.070.2-0.060.13
Other Long-Term Liabilities
--8.8112.31-
Total Long-Term Liabilities
0.070.28.8112.370.13
Total Liabilities
85.85107.1262.1850.211.36
Common Stock
14.2813.4410.1710.0695.38
Additional Paid-in Capital
1,4271,298670.78635.640.67
Accumulated Other Comprehensive Income
4.794.470.470.47-
Retained Earnings
-762.39-558.57-307.98-129.37-39.43
Shareholders' Equity
683.43757.5373.44516.7956.62
Total Liabilities & Equity
769.28864.62435.62566.9967.98
Total Debt
0.20.450.060.130.19
Net Cash (Debt)
636.04833.74340.39467.660.19
Net Cash Growth
-23.71%144.94%-27.21%676.92%-
Net Cash Per Share
5.378.844.1411.802.55
Book Value
683.43757.5373.44516.7956.62
Book Value Per Share
5.778.034.5513.042.40
Tangible Book Value
683.02756.97284.74428.0956.62
Tangible Book Value Per Share
5.778.023.4710.802.40
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q